Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema
Clinically significant macular edema (CSME) is a thickening of the macula associated with the risk of visual loss, which increases its centre is involved. Functional evaluation of the macula relies on best corrected visual acuity; however, neural dysfunction in diabetic eyes appears before retinal thickening and visual loss. Retinal sensitivity decreases in eyes with CSME, but it is unknown whether it differs between eyes with and without centre thickening.
Aim: To compare the reduction of foveal sensitivity in eyes with CSME, with and without centre thickening.
|Diabetic Retinopathy Clinically Significant Macular Edema|
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Target Follow-Up Duration:||1 Day|
|Official Title:||Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Oedema, With and Without Centre Involvement|
- foveal sensitivity [ Time Frame: 1 day ]the ability of the fovea to perceive a light stimulus in 16 central points, which is measured in dB with a 10 degree central macular perimetry
- Retinal thickness [ Time Frame: 1 day ]measured in µm, according to the automatic value generated by the fast macular map of the optical coherence tomography
|Study Start Date:||January 2013|
|Study Completion Date:||July 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
eyes without diabetic retinopathy
eyes of patients with diabetes mellitus type 2 that does not have retinopathy
CSME without centre involvement
eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
CSME with centre involvement
eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
A non-experimental, comparative, prospective, cross-sectional study was conducted. Target population were type 2 diabetics, from Mexico City and its metropolitan area, and available population were type 2 diabetics who attended an Ophthalmology service from a general hospital in Mexico City, from September 2011 to May 2012.
Type 2 diabetic patients aged 30-85 years, from any gender, with central fixation, whose ocular media allowed obtaining an adequate quality Optical Coherence Tomography, who had CSME with focal angiographic pattern were included. Eyes with optic nerve or visual pathways diseases or any other ocular disease that decreased Best corrected visual acuity, were excluded. Diabetic patients without retinopathy who fulfilled the remaining selection criteria were evaluated as the reference group.
Sixty degrees colour fundus photographs were obtained in all the patients using a Visucam lite ocular fundus camera; in group 1 it was verified that no signs of diabetic retinopathy existed in the photographs; CSMO was diagnosed by biomicroscopy under mydryasis, according to the ETDRS criteria.
Retinal thickness was measured using Stratus optical coherence tomography (OCT), version 4.0.1 (Zeiss). The 6 mm fast macular map strategy was used, according to the following standardised operating procedure: mydriasis ≥6mm, inclusion of the spherical equivalent and anteroposterior axis, and optimisation of z axis and of polarisation; the photograph was taken with flash between 9:00 and 11:00, using an acquisition strategy for dark irises. The maps were obtained by the same investigator, independent from the one who evaluated the patients clinically; any deviation of the OCT line regarding the actual retina boundary was considered as a measurement error.
A 10° macular perimetry was obtained in all the patients, using a Humphrey field analyser model 750i (software version 4.1); the sixteen points evaluated were arbitrarily labelled. Retinal thickness within 3 mm from the centre of the fovea was measured in 9 fields, according to the fast macular map.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01824862
|Virgilio Lima Gomez|
|Mexico, Distrito Federal, Mexico, 07760|
|Study Chair:||VIRGILIO LIMA GOMEZ, PhD||Hospital Juarez de Mexico|
|Principal Investigator:||Dulce M Razo Blanco Hernandez, MSc||Hospital Juárez de México|